Vaccination to prevent varicella and shingles

Journal of Clinical Pathology

Volumn 54, Issue 10, 2001, Pages 743-747

  Breuer, J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chickenpox; Herpes zoster; Leukaemia; Vaccination; Varicella zoster

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE; VARICELLA ZOSTER VACCINE;

CANADA; CHICKENPOX; CHILD; DRUG SAFETY; GERMANY; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; JAPAN; PRIORITY JOURNAL; REVIEW; SOUTH KOREA; SWEDEN; UNITED STATES; VIRUS STRAIN;

EID: 0034805551     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.10.743     Document Type: Review

References (62)

1. Varicella: Complications and costs
2. Varicella-zoster virus: Prospects for control
3. Varicella in children with cancer: Seventy-seven cases
4. Live vaccine used to prevent the spread of varicella in children in hospital
5. Review of recommendations of the advisory committee on immunization practices, centers for the disease control and prevention, on varicella vaccine
6. Experience and reason: Twenty year follow up of protective immunity of the Oka live varicella vaccine
7. Immunization to reduce the frequency and severity of herpes zoster and its complications
8. Ability of yeast Ty-VLPs (virus-like particles) containing varicella-zoster protein fragments to induce in vitro proliferation of human lymphocytes
9. Immunization with a DNA expression vector encoding the varicella zoster virus glycoprotein E (gE) gene via intramuscular and subcutaneous routes
10. Analysis of immune responses to varicella zoster viral proteins induced by DNA vaccination
11. Production and quality control of the Oka-strain live varicella vaccine
12. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse
13. Infection of human T lymphocytes with varicella-zoster virus: An analysis with viral mutants and clinical isolates
14. Biological and biophysical markers of a live varicella vaccine strain (Oka): Identification of clinical isolates from vaccine recipients
15. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates
16. Analysis of United Kingdom wild-type strains of varicella-zoster virus: Differentiation from the Oka vaccine strain
17. Identification of varicella-zoster virus strains by PCR analysis of three repeat elements and a PstI-site-less region
18. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates
19. Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies
20. Live attenuated varicella vaccine
21. Varicella vaccine: The American experience
22. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection
23. Laboratory markers of immunity to varicella-zoster virus
24. Immune responses to varicella-zoster in the aged
25. Efficacy, immunogenicity, safety and use of live attenuated chickenpox vaccine
26. Risk factors for breakthrough varicella in healthy children
27. Live attenuated varicella virus vaccine: Efficacy trial in healthy children
28. Modified cases of chickenpox after varicella vaccination: Correlation of protection with antibody response
29. Postmarketing evaluation of the safety and effectiveness of varicella vaccine
30. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia
31. Prevention of varicella. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)
32. Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989
33. Antibody assays suitable for assessing immune response to live varicella vaccine
34. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine
35. Varicella-zoster virus (VZV)-specific cytotoxicity after immunisation of nonimmune adults with Oka strain attenuated VZV vaccine
36. Varicella vaccine for immunocompromised children: Results of collaborative studies in the United States and Canada
37. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia
38. The protective effect of imunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox
39. Immunological evidence of reinfection with varicella-zoster virus
40. The epidemiology of varicella-zoster virus infections: A mathematical model
41. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation
42. Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children
43. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine
44. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization
45. The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine
46. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content
47. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children
48. Combination measles, mumps, rubella and varicella vaccine
49. Risk of herpes zoster in children with leukemia: Varicella vaccine compared with history of chickenpox
50. Herpes zoster in an adult recipient of live attenuated varicella vaccine
51. Immune response of elderly individuals to a live attenuated varicella vaccine
52. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine
53. A dose response study of a live attenuated varicella-zoster virus (oka strain) vaccine administered to adults 55 years and older
54. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine
55. A benefit-cost analysis of childhood varicella vaccination programme
56. Childhood vaccination against chickenpox: An analysis of benefits and costs
57. Cost-effectiveness of a routine varicella vaccination program of US children
58. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents
59. Costs and benefits of routine varicella vaccination in German children
60. Outcome after maternal varicella infection in the first 20 weeks of pregnancy
61. Varicella vaccine in pregnancy
62. Controlling chickenpox in hospitals